文献速递神经免疫

COVID-19中吉兰-巴雷综合征的发病率、临床特征、危险因素和结局

Incidence, clinical, risk factors and outcomes of Guillain-Barré in Covid-19.
PubMed 文献 · Ann Neurol · 2020-12-28

在西班牙61家急诊科疫情期间,71,904例COVID患者中诊断11例吉兰-巴雷综合征(GBS)。COVID患者中GBS相对频率(0.15‰)高于非COVID患者(0.02‰),OR=6.30(95%CI 3.18-12.5);标准化发病率分别为9.44和0.69例/10万居民年,OR=13.5(95%CI 9.87-18.4)。COVID-GBS患者嗅觉-味觉障碍更常见,更常入住ICU,但死亡率未增加。

要点

  • COVID患者中GBS相对频率(0.15‰)高于非COVID患者(0.02‰),OR=6.30。
  • COVID患者GBS标准化发病率9.44例/10万居民年,非COVID为0.69例/10万居民年。
  • COVID-GBS患者嗅觉-味觉障碍更常见,更常入住ICU,但死亡率未增加。

核心结论

  • SARS-CoV-2可能是另一种引起吉兰-巴雷综合征的病毒感染。

研究设计与样本

  • 在西班牙61家急诊科为期2个月的大流行高峰期,纳入71,904例COVID患者,诊断11例GBS。

主要发现

  • COVID患者中GBS相对频率为0.15‰,非COVID患者为0.02‰,OR=6.30(95%CI 3.18-12.5)。
  • COVID患者GBS标准化发病率为9.44例/10万居民年,非COVID患者为0.69例/10万居民年,OR=13.5(95%CI 9.87-18.4)。
  • COVID-GBS患者嗅觉-味觉障碍比非COVID-GBS更常见(OR=27.59,95%CI 1.296-587),也比COVID非GBS更常见(OR=7.875,95%CI 1.587-39.09)。
  • COVID-GBS患者更常入住ICU,但死亡率与对照组相比未增加。

临床怎么用

  • 急诊遇到COVID-19患者出现GBS症状时应考虑SARS-CoV-2相关GBS可能。
  • COVID-GBS患者需关注ICU入住风险,但死亡率未见增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We diagnosed 11 Guillain-Barré syndrome (GBS) cases among 71,904 COVID patients attended at 61 Spanish emergency departments (EDs) during the 2-month pandemic peak. The relative frequency of GBS among ED patients was higher in COVID (0.15‰) than non-COVID (0.02‰) patients (odds ratio [OR] = 6.30, 95% confidence interval [CI] = 3.18-12.5), as was the standardized incidence (9.44 and 0.69 cases/100,000 inhabitant-years, respectively, OR = 13.5, 95% CI = 9.87-18.4). Regarding clinical characteristics, olfactory-gustatory disorders were more frequent in COVID-GBS than non-COVID-GBS (OR = 27.59, 95% CI = 1.296-587) and COVID-non-GBS (OR = 7.875, 95% CI = 1.587-39.09) patients. Although COVID-GBS patients were more frequently admitted to intensive care, mortality was not increased versus control groups. Our results suggest SARS-CoV-2 could be another viral infection causing GBS. ANN NEUROL 2021;89:598-603.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Fragiel M, Miró Ò, Llorens P, et al. Incidence, clinical, risk factors and outcomes of Guillain-Barré in Covid-19. Ann Neurol. 2020. PMID: 33295021. doi:10.1002/ana.25987

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。